Additional Studies Needed To Evaluate CVD Risks Of Hormone Therapy For Transgender Patients

A new narrative review authored by Carl Streed Jr., MD, at Brigham and Women's Hospital, published in the Annals of Internal Medicine, discusses how more research is needed to better understand cardiovascular disease (CVD) and CVD risk factors in transgender patients receiving long term cross-sex hormone therapy.

Researchers at BWH and Johns Hopkins Hospital reviewed 13 studies on the effect of cross-sex hormone therapy on CVD among transgender persons. In transgender men, cross-sex hormone therapy was associated with worsening cardiovascular risk factors, such as increased blood pressure and insulin resistance. In transgender women, cross-sex hormone therapy increased potential thromboembolic risk. For both transgender men and women, the researchers say it is critical to reduce cardiovascular risk factors to prevent CVD, but especially in older transgender women.

According to the authors, cross-sex hormone therapy is associated with potential risks, but its psychosocial benefits cannot be denied. Use of cross-sex hormone therapy requires continued, shared decision making between patients and clinicians. To evaluate the difference among various cross-sex hormone therapy regimens, they note future research should be based on large prospective cohort studies that include cisgender men and women, transgender men and women receiving cross-sex hormone therapy, and transgender men and women not receiving cross-sex hormone therapy.


Explore further

Transgender women who begin hormone therapy more likely to quit smoking

Journal information: >Annals of Internal Medicine >

Provided by Brigham and Women's Hospital >

Citation: Additional studies needed to evaluate CVD risks of hormone therapy for transgender patients (2017, July 24) retrieved 17 June 2019 from https://medicalxpress.com/news/2017-07-additional-cvd-hormone-therapy-transgender.html

Source : https://medicalxpress.com/news/2017-07-additional-cvd-hormone-therapy-transgender.html

Additional studies needed to evaluate CVD risks of hormone therapy for transgender patients
Gender transition hormone therapy may increase cardiovascular risk
Research Needed to Assess CV Risks of Transgender Hormone Therapy
New study finds life-threatening risk in transgender hormone therapy
Additional studies needed to evaluate CVD risks of hormone therapy for transgender patients
Are transgender men and women who take hormones at risk for heart disease?
Hormone therapy may increase cardiovascular risk during gender transition
Hormone therapy during gender transition may increase risk for cardiovascular events